1
|
Yu MC and Yuan JM: Epidemiology of
nasopharyngeal carcinoma. Semin Cancer Biol. 12:421–429. 2002.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Lo AK, Dawson CW, Jin DY and Lo KW: The
pathological roles of BART miRNAs in nasopharyngeal carcinoma. J
Pathol. 227:392–403. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Lee AW, Poon YF, Foo W, et al:
Retrospective analysis of 5037 patients with nasopharyngeal
carcinoma treated during 1976–1985: overall survival and patterns
of failure. Int J Radiat Oncol Biol Phys. 23:261–270.
1992.PubMed/NCBI
|
4
|
Hui EP, Leung SF, Au JS, et al: Lung
metastasis alone in nasopharyngeal carcinoma: a relatively
favorable prognostic group. A study by the Hong Kong Nasopharyngeal
Carcinoma Study Group Cancer. 101:300–306. 2004.PubMed/NCBI
|
5
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar
|
6
|
Li G, Wu Z, Peng Y, et al: MicroRNA-10b
induced by Epstein-Barr virus-encoded latent membrane protein-1
promotes the metastasis of human nasopharyngeal carcinoma cells.
Cancer Lett. 299:29–36. 2010. View Article : Google Scholar
|
7
|
Deng M, Tang H, Zhou Y, et al: miR-216b
suppresses tumor growth and invasion by targeting KRAS in
nasopharyngeal carcinoma. J Cell Sci. 124:2997–3005. 2011.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Wong TS, Man OY, Tsang CM, et al: MicroRNA
let-7 suppresses nasopharyngeal carcinoma cells proliferation
through down-regulating c-Myc expression. J Cancer Res Clin Oncol.
137:415–422. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lu J, He ML, Wang L, et al: MiR-26a
inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma
through repression of EZH2. Cancer Res. 71:225–233. 2011.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Tong ZT, Cai MY, Wang XG, et al: EZH2
supports nasopharyngeal carcinoma cell aggressiveness by forming a
co-repressor complex with HDAC1/HDAC2 and Snail to inhibit
E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Alajez NM, Shi W, Hui AB, et al: Enhancer
of Zeste homolog 2 (EZH2) is overexpressed in recurrent
nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and
miR-98. Cell Death Dis. 1:e852010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Liu T, Ding Y, Xie W, et al: An imageable
metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer
Res. 13:3960–3967. 2007. View Article : Google Scholar : PubMed/NCBI
|
14
|
Li XP, Li CY, Li X, et al: Inhibition of
human nasopharyngeal carcinoma growth and metastasis in mice by
adenovirus-associated virus-mediated expression of human
endostatin. Mol Cancer Ther. 5:1290–1298. 2006. View Article : Google Scholar
|
15
|
Li W, Yuan Y, Huang L, Qiao M and Zhang Y:
Metformin alters the expression profiles of microRNAs in human
pancreatic cancer cells. Diabetes Res Clin Pract. 96:187–195. 2012.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Dang X, Ma A, Yang L, et al: MicroRNA-26a
regulates tumorigenic properties of EZH2 in human lung carcinoma
cells. Cancer Genet. 205:113–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Liu B, Wu X, Wang C, Liu Y, Zhou Q and Xu
K: MiR-26a enhances metastasis potential of lung cancer cells via
AKT pathway by targeting PTEN. Biochim Biophys Acta.
1822:1692–1704. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Viré E, Brenner C, Deplus R, et al: The
Polycomb group protein EZH2 directly controls DNA methylation.
Nature. 439:871–874. 2006.PubMed/NCBI
|
19
|
Varambally S, Dhanasekaran SM, Zhou M, et
al: The polycomb group protein EZH2 is involved in progression of
prostate cancer. Nature. 419:624–629. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kleer CG, Cao Q, Varambally S, et al: EZH2
is a marker of aggressive breast cancer and promotes neoplastic
transformation of breast epithelial cells. Proc Natl Acad Sci USA.
100:11606–11611. 2003. View Article : Google Scholar : PubMed/NCBI
|
21
|
Pietersen AM, Horlings HM, Hauptmann M, et
al: EZH2 and BMI1 inversely correlate with prognosis and TP53
mutation in breast cancer. Breast Cancer Res. 10:R1092008.
View Article : Google Scholar : PubMed/NCBI
|